US Royalty Pharma strikes deal with PureTech Health on KarXT royalties
23rd Mar 2023 07:24
(Sharecast News) - US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.
Read morePureTech's Alkili reports success in adolescent ADHD study
6th Jan 2023 18:31
(Sharecast News) - Clinical-stage biotherapeutics investor PureTech Health announced on Friday today that its digital medicine company Akili, which it founded, announced topline results of the 'STARS-ADHD-Adolescents' label expansion study evaluating the efficacy and safety of 'EndeavorRx', or 'AKL-T01' in adolescents aged 13 to 17 with attention-deficit hyperactivity disorder (ADHD).
Read morePuretech, Nektar Therapeutics end merger talks
11th Oct 2022 07:05
(Sharecast News) - Shares in healthcare company PureTech fell on Tuesday as the company said it and US-based Nektar Therapeutics had ended merger talks only four days after they announced a potential tie up.
Read morePuretech Health confirms possible tie-up with Nektar Therapeutics
7th Oct 2022 07:10
(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.
Read morePuretech Health confirms possible tie-up with Nektar Therapeutics
7th Oct 2022 07:10
(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.
Read morePureTech first-half mixed as it makes good clinical progress
25th Aug 2022 09:25
(Sharecast News) - PureTech Health reported total first-half revenue of $7.03m on Thursday, up from $5.84m year-on-year.
Read morePureTech reports 'Glyph' milestone, disappointing long Covid results
14th Jun 2022 07:33
(Sharecast News) - PureTech Health said on Tuesday that it had met a milestone in proving its 'Glyph' therapeutic platform, while separately announcing disappointing results from a study into long Covid.
Read morePureTech to buy back up to $50m of shares
5th May 2022 10:09
(Sharecast News) - PureTech Health has announced a $50m share buyback programme, sending shares in the FTSE 250 biotech sharply higher.
Read morePuretech Health receives $100m from sale of 55% stake in Karuna Therapeutics
10th Nov 2021 09:15
(Sharecast News) - Biotechnology company Puretech Health has received approximately $100.0m in cash from the sale of a portion of the group's shares in its founded entity Karuna Therapeutics.
Read morePureTech Health's Vor wins FDA fast-track approval for cancer drug
10th Sep 2021 07:38
(Sharecast News) - Clinical stage biotherapeutics firm PureTech Health on Friday said its founded entity, Vor Biopharma, had won US fast track approval for its leukaemia treatment.
Read moreTuesday broker round-up
24th Aug 2021 14:34
(Sharecast News) - Coats: Jefferies starts at buy with 97.0p target price.
Read morePureTech in 'strong' position despite swinging to net loss
24th Aug 2021 07:42
(Sharecast News) - Biotechnology company PureTech Health swung to a loss in its first half, it said on Tuesday, amid rising costs.
Read moreDirector dealings: Puretech Health director raises stake
22nd Jul 2021 15:35
(Sharecast News) - Puretech Health revealed on Thursday that director Bharatt Chowrira had acquired 25,000 ordinary shares in the FTSE 250-listed biotechnology company.
Read morePuretech Health narrows FY operating losses after cutting expenses
15th Apr 2021 07:52
(Sharecast News) - Biotechnology company Puretech Health said on Thursday that it had narrowed operating losses in 2020 on the back of a reduction in general and administrative expenses and a modest increase in full-year revenues.
Read morePureTech sells down Karuna stake as Vor closes IPO
10th Feb 2021 09:22
(Sharecast News) - Clinical-stage biotherapeutics commercialisation company PureTech Health announced on Wednesday that its founded entity Vor Biopharma has closed its initial public offering at a price of $18 per share.
Read more